Disparities in the treatment of patients with IL-2 for metastatic renal cell carcinoma

Urologic Oncology: Seminars and Original Investigations

Volumn 28, Issue 3, 2010, Pages 308-313

  Saigal, Christopher S ^a   Deibert, Christopher M ^b   Lai, Julie ^c   Schonlau, Matthias ^c  

^a UCLA MEDICAL CENTER   (United States)

^b UNIVERSITY OF ARIZONA COLLEGE OF MEDICINE   (United States)

^c RAND CORPORATION   (United States)

Author keywords

Disparities care; IL 2; Renal cell cancer

Indexed keywords

INTERLEUKIN 2;

ADULT; AFRICAN AMERICAN; AGED; ARTICLE; CANCER IMMUNOTHERAPY; CANCER MORTALITY; FEMALE; HEALTH DISPARITY; HUMAN; KIDNEY CARCINOMA; MAJOR CLINICAL STUDY; MALE; MARRIAGE; NEPHRECTOMY; PRIORITY JOURNAL; RACE DIFFERENCE; SEX DIFFERENCE; SURVIVAL RATE;

AFRICAN AMERICANS; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; CARCINOMA, RENAL CELL; EUROPEAN CONTINENTAL ANCESTRY GROUP; FEMALE; HEALTHCARE DISPARITIES; HUMANS; INTERLEUKIN-2; KIDNEY NEOPLASMS; LOGISTIC MODELS; MALE; MIDDLE AGED; SEER PROGRAM; SEX FACTORS; SOCIOECONOMIC FACTORS; UNITED STATES;

EID: 77951552891     PISSN: 10781439     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.urolonc.2008.09.022     Document Type: Article

References (17)

1. Chow W.H., Devesa S.S., Warren J.L., et al. Rising incidence of renal cell cancer in the United States. JAMA 281 (1999) 1628-1631
2. Bretheau D., Lechevallier E., Eghazarian C., et al. Prognostic significance of incidental renal cell carcinoma. Eur Urol 27 (1995) 319-323
3. Homma Y., Kawabe K., Kitamura T., et al. Increased incidental detection and reduced mortality in renal cancer-recent retrospective analysis at eight institutions. Int J Urol 2 (1995) 77-80
4. Jayson M., and Sanders H. Increased incidence of serendipitously discovered renal cell carcinoma. Urology 51 (1998) 203-205
5. Klapper J.A., Downey S.G., Smith F.O., et al. High-dose interleukin-2 for the treatment of metastatic renal cell carcinoma: a retrospective analysis of response and survival in patients treated in the surgery branch at the National Cancer Institute between 1986 and 2006. Cancer 113 (2008) 293-301
6. Warren J.L., Klabunde C.N., Schrag D., et al. Overview of the SEER-Medicare data: content, research applications, and generalizability to the United States elderly population. Med Care 40 Suppl IV (2002) 3-18
7. Bach P.B., Guadagnoli E., Schrag D., et al. Patient demographic and socioeconomic characteristics in the SEER-Medicare database applications and limitations. Med Care 40 Suppl IV (2002) 19-25
8. Klabunde C.N., Potosky A.L., Legler J.M., et al. Development of a comorbidity index using physician claims data. J Clin Epidemiol 53 (2000) 1258-1267
9. Greenberg E.R., Chute C.G., Stukel T., et al. Social and economic factors in the choice of lung cancer treatment. A population-based study in two rural states. N Engl J Med 318 (1988) 612-617
10. Osborne C., Ostir G.V., Du X., et al. The influence of marital status on the stage at diagnosis, treatment, and survival of older women with breast cancer. Breast Cancer Res Treat 93 (2005) 41-47
11. McDermott D.F., Regan M.M., Clark J.I., et al. Randomized phase III trial of high-dose interleukin-2 vs. subcutaneous interleukin-2 and interferon in patients with metastatic renal cell carcinoma. J Clin Oncol 23 (2005) 133-141
12. Atkins M.B., Dutcher J., Weiss G., et al. Kidney cancer: The Cytokine Working Group experience (1986-2001): Part I. IL-2-based clinical trials. Med Oncol 18 (2001) 197-207
13. Vaishampayan U.N., Do H., Hussain M., et al. Racial disparity in incidence patterns and outcome of kidney cancer. Urology 62 (2003) 1012-1017
14. Tripathi R.T., Heilbrun L.K., Jain V., et al. Racial disparity in outcomes of a clinical trial population with metastatic renal cell carcinoma. Urology 68 (2006) 296-301
15. Wong A.S., Chong K.T., Heng C.T., et al. Debulking nephrectomy followed by a "watch and wait" approach in metastatic renal cell carcinoma. Urol Oncol 27 (2009) 149-154
16. Neill M.G., and Jewett M.A. The once and future role of cytoreductive nephrectomy. Urol Oncol 26 (2008) 346-352
17. Remak E., Charbonneau C., Negrier S., et al. Economic evaluation of sunitinib malate for the first-line treatment of metastatic renal cell carcinoma. J Clin Oncol 26 (2008) 3995-4000